MGC Pharmaceuticals Limited Results of Shareholder's General Meeting (3819E)

TIDMMXC

RNS Number : 3819E

MGC Pharmaceuticals Limited

29 June 2023

MGC Pharmaceuticals Ltd.

Results of Shareholder's General Meeting

29 June 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the voting results from the Company's General Meeting of shareholders, held today Thursday 29 June 2023.

The Company advises that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the results can be found in the following URL:

https://www.investi.com.au/api/announcements/mxc/79666683-5ff.pdf

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

 
 MGC Pharmaceuticals Ltd                        MGC Pharmaceuticals Ltd 
  Roby Zomer                                     Arron Canicais / Rowan Harland 
  CEO & Managing Director                        Joint Company Secretaries 
  +61 8 6382 3390                                +61 8 6382 3390 
  info@mgcpharma.co.uk                           info@mgcpharma.co.uk 
 UK Brokers                                     UK Brokers 
  Peterhouse Capital                             Oberon Capital 
  Charles Goodfellow / Lucy Williams             Aimee McCusker / Adam Pollock 
  / Duncan Vasey                                 +44 203 179 5300 
  +44 207 469 0930                               aimeemccusker@oberoninvestments.com 
  cg@peterhousecap.com / lw@peterhousecap.com    adampollock@oberoninvestments.com 
 UK IR/PR Advisers 
  IFC Advisory 
  Graham Herring / Tim Metcalfe / 
  Zach Cohen 
  +44 203 934 6630 
  mgcpharma@investor-focus.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMUKAKROWUNURR

(END) Dow Jones Newswires

June 29, 2023 05:22 ET (09:22 GMT)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Jun 2024 to Jul 2024